EXL01 in the Maintenance of Steroid-induced Clinical Response/Remission in Participants With Mild to Moderate Crohn's Disease (MAINTAIN)
A Phase 1, Multicentre, 2-Part, Randomised, Parallel-arm, Placebo-controlled, Partially Double-blind Study to Evaluate the Safety and Target Engagement of EXL01 in the Maintenance of Steroid-induced Clinical Response or Remission in Participants With Mild to Moderate Crohn's Disease
Sponsor: Alimentiv Inc.
Terminated
Due to low recruitment
Other terminated trials from Alimentiv Inc.
More terminations from Alimentiv Inc.
Listed as NCT05542355, this PHASE1 trial focuses on Crohn Disease and remains terminated or withdrawn. Sponsored by Alimentiv Inc., it has been updated 11 times since 2023, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE1
-
Nov 2024 — Sep 2025 [monthly]
Terminated PHASE1
Status: Active Not Recruiting → Terminated
-
Sep 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Dec 2023 — Jul 2024 [monthly]
Recruiting PHASE1
▶ Show 6 earlier versions
-
Apr 2023 — Dec 2023 [monthly]
Recruiting PHASE1
-
Mar 2023 — Apr 2023 [monthly]
Recruiting PHASE1
-
Feb 2023 — Mar 2023 [monthly]
Recruiting PHASE1
-
Jan 2023 — Feb 2023 [monthly]
Recruiting PHASE1
-
Nov 2022 — Jan 2023 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Sep 2022 — Nov 2022 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Alimentiv Inc.
- Exeliom Biosciences
For direct contact, visit the study record on ClinicalTrials.gov .